APS Insider Trading (Aptose Biosciences)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$65,040.15
Insider Selling (Last 12 Months): C$0.00
Aptose Biosciences Share Price & Price History
Current Price: C$0.97
Price Change: ▼ Price Decrease of -0.05 (-4.90%)
As of 06/30/2022 02:01 PM ET
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.
Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.
Aptose Biosciences Insider Trading History
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|6/6/2022||William Glenn Rice||Director||Buy||2,776||C$1.22||C$3,375.69||346,028|
|12/16/2021||William Glenn Rice||Director||Buy||3,183||C$1.92||C$6,111.36||333,252|
|11/26/2021||William Glenn Rice||Director||Buy||1,000||C$3.07||C$3,069.00||304,604|
|11/19/2021||Rafael Bejar||Senior Officer||Buy||10,000||C$3.38||C$33,792.00||10,000|
|7/10/2020||Gregory Kwok Lee Chow||Senior Officer||Sell||126,668||C$8.47||C$1,072,877.96||232,846|
|7/10/2020||William Glenn Rice||Director||Sell||168,891||C$8.47||C$1,430,506.77||297,523|
|10/24/2019||William Glenn Rice||Director||Buy||10,000||C$2.53||C$25,344.00||163,014|
Former Lawyer Went From $50K To $5.3M Trading Options
Slaving away for 70 hrs a week as a lawyer in Chicago, I was miserable.
I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually).
I grew my $50K into $5.3M
I'll show you how I did it here.
SEC Filings (Institutional Ownership Changes) for Aptose Biosciences (TSE:APS)
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
50 Day Range
52 Week Range
Who are the company insiders with the largest holdings of Aptose Biosciences?